As the coronavirus pandemic claims lives and overwhelms health care systems throughout the world, scientists are closely watching several late-stage trials of the antiviral drug remdesivir. Developed to treat Ebola, remdesivir is now being tested against COVID-19. However, many infectious disease experts caution that the trials are unlikely to yield clear-cut results, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.
Gilead Sciences discovered remdesivir during the 2014 Ebola outbreak in West Africa. Although the drug was not effective in treating late-stage Ebola, it was shown to be fairly safe, Senior Correspondent Lisa Jarvis writes. Remdesivir blocks an enzyme called RNA polymerase that the Ebola virus -- and other RNA viruses, including SARS-CoV-2 -- uses to replicate. Scientists have already shown in lab experiments and animal studies that the drug can help treat and prevent infections of the coronaviruses that cause SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Despite hints that remdesivir could also kill SARS-CoV-2, results from current clinical trials will likely be difficult to interpret, experts say.
Of the five Phase III studies testing remdesivir against COVID-19, two began in China in early February, one in the U.S. in February and two more in the U.S. in March. Because four of the five studies enrolled patients with moderate-to-severe diseases, which are more difficult to treat than milder cases, a failure of the drug in these trials doesn't necessarily mean it wouldn't work for patients treated earlier in the course of infection. Although the U.S. Food and Drug Administration typically takes 6-12 months to approve new drugs, the process will likely be expedited if results from these clinical trials look promising, according to experts.
###
The article, "What can initial remdesivir data tell us about tackling COVID-19?," is freely available here.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
Journal
Chemical & Engineering News